Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2012

Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2012', provides an overview of the Muscle Invasive Bladder Cancer (MIBC) therapeutic pipeline. This report provides information on the therapeutic development for Muscle Invasive Bladder Cancer (MIBC), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscle Invasive Bladder Cancer (MIBC). 'Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Muscle Invasive Bladder Cancer (MIBC).
- A review of the Muscle Invasive Bladder Cancer (MIBC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Muscle Invasive Bladder Cancer (MIBC) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Muscle Invasive Bladder Cancer (MIBC).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Muscle Invasive Bladder Cancer (MIBC) pipeline depth and focus of Muscle Invasive Bladder Cancer (MIBC) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Muscle Invasive Bladder Cancer (MIBC) Therapeutic Products under Development, Key Players in Muscle Invasive Bladder Cancer (MIBC) Therapeutics, Muscle Invasive Bladder Cancer (MIBC) Pipeline Overview, Muscle Invasive Bladder Cancer (MIBC) Pipeline, Muscle Invasive Bladder Cancer (MIBC) Pipeline Assessment SHOW LESS READ MORE >

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Muscle Invasive Bladder Cancer (MIBC) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) 7
Muscle Invasive Bladder Cancer (MIBC) Therapeutics under Development by Companies 9
Muscle Invasive Bladder Cancer (MIBC) Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Muscle Invasive Bladder Cancer (MIBC) Therapeutics – Products under Development by Companies 15
Muscle Invasive Bladder Cancer (MIBC) Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Muscle Invasive Bladder Cancer (MIBC) Therapeutics Development 17
Altor BioScience Corporation 17
Muscle Invasive Bladder Cancer (MIBC) – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
Gemcitabine + Cisplatin + Sunitinib - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Mitomycin C - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ALT-801 + Gemcitabine + Cisplatin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
TD1770 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables
Number of Products Under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2012 7
Products under Development for Muscle Invasive Bladder Cancer (MIBC) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Altor BioScience Corporation, H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23

List of Figures
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2012 7
Products under Development for Muscle Invasive Bladder Cancer (MIBC) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23